We were among the first to report that frequencies and phenotypes of myeloid cells were rapidly altered in response to anti-CTLA-4 blocking antibody Ipilimumab in melanoma patients and could be correlated to poor treatment outcome.39-41. The gene discussed is CTLA4; the disease is melanoma.